What are you
looking for?

Ad hoc
Media Release Jul 10, 2024
Marcel Imwinkelried appointed as new CEO
Media Release Jul 02, 2024
Siegfried successfully completes acquisition of an early-phase CDMO in Wisconsin (US)
Ad hoc
Media Release Jun 14, 2024
EGS Beteiligungen AG exercises right to convert bond and increases its shareholding in Siegfried to 6.2% registered shares
Ad hoc
Media Release Jun 12, 2024
Siegfried to acquire an early-phase CDMO in Wisconsin (US) to strengthen its Drug Substances service offering
Media Release Apr 18, 2024
Siegfried increases distribution to the shareholders and all proposals of the Board of Directors are approved
Ad hoc
Media Release Apr 02, 2024
Changes in Siegfried’s Management Team
Ad hoc
Media Release Feb 20, 2024
Siegfried continues to deliver profitable growth
Media Release Feb 02, 2024
Changes in Siegfried’s Senior Management Team
Media Release Dec 13, 2023
Siegfried confirmed in the Dow Jones Sustainability Index Europe for the third consecutive year
Ad hoc
Media Release Aug 17, 2023
Siegfried delivers strong sales growth and profitability in first half 2023
Media Release May 15, 2023
Changes in Siegfried’s Executive Committee
Ad hoc
Media Release May 04, 2023
Siegfried acquires majority stake in DINAMIQS to establish a best-in-class development and manufacturing organization for cell and gene therapies

at a glance

As a globally leading contract and development manufacturing organization, we produce pharmaceutical ingredients and finished products as an integrated supplier.

The most trusted partner in the pharmaceutical industry

Siegfried offers contract developing and manufacturing of active pharmaceutical ingredients, intermediates and finished dosage forms. Our integrated approach ensures that we can provide a range of services, from process development and optimization to registration, production, packaging and logistics.

Learn more

A global network of excellence

Siegfried counts on a global network of 13 facilities in seven countries on three continents for the production of active pharmaceutical ingredients and intermediates (Drug Substances) and finished dosage forms (Drug Products).

Learn more

Ensuring safe drugs for patients worldwide

Siegfried supplies approximately 200 out of 1500 APIs approved by the FDA. We serve more than 500 customers globally, and up to one billion people come in contact with Siegfried products every year. Over 100 million doses of Covid-19 vaccines have been manufactured by Siegfried.

Learn more

Determined to develop greener production processes

We are committed to reducing our carbon footprint in close collaboration with our customers. With our expertise in process optimization, we help our customers to develop greener production processes, which require less energy and produce less waste while maximizing the safety of our products. Siegfried is a member of the Dow Jones Sustainability Index Europe and rated AA by MSCI.

Learn more

150 years of expertise

Founded in 1873 by pharmacist Samuel Benoni Siegfried in Zofingen, Switzerland, the company has been growing steadily ever since. Siegfried evolved into a global player with state-of-the-art facilities and cutting-edge technologies through the strategic acquisitions.

Learn more


Let's get in touch

Reto Suter
Chief Financial Officer
Peter Stierli
Head Corporate Communications
To top